2014 will be a strong year for Novartis: CEO

Joe Jimenez, CEO of Novartis, confirms the company's 2014 outlook, saying sales growth will be in the mid-single digits in the "worst case scenario" that there is generic competition to its blood pressure pill Diovan "relatively soon".